TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Self-Reported Functioning
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Yale Brown Obsessive-Compulsive Scale (Y-BOCS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Enrollment of children with ASBI and PSH
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Study retention of children with ASBI and PSH
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Device tolerability for children with ASBI and PSH
Endpoint domain: Adverse events/effects
Primary endpoint: Assessment of PSH symptoms using CFS scoring tool
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Detection of inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Successful Reversion to Sinus Rhythm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction in calprotectin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the functional component score of the Late-Life Functional Disability Index (LLFDI)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Admission to a care home
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Physical care
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Psychological care
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Social care
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: HAMD-17 score reduction rate ≥50%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: post-operative pulmonary complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: post-operative cardiovascular complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in gamma brain oscillations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Affiliation with Sickle cell disease (SCD)-specific care
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Primary patency at 6 months post-procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Major adverse events (MAE) at 6 months post-procedure
Endpoint domain: Adverse events/effects
Primary endpoint: reduction in pruritus area and severity Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: safety of upadacitinib
Endpoint domain: Adverse events/effects
Primary endpoint: global assessment (IGA)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: R0 retroperitoneal margin rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: R0 transection margin rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Lymph node positive rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Trait anger and anger expression styles
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: COVID-19 serology IgG levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Reduction in Radiation Dermatitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in the total number of clinically significant drug-drug interactions (DDIs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the number of clinically significant DDIs between antiretroviral drugs and drugs of specific therapeutic classes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of warts complete clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximal Mouth Opening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative residual limb pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative phantom limb pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative pain behavior
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative pain interference
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change from baseline in mid-upper arm circumference (MUAC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weight-for-height z-score (WHZ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bilateral pitting edema
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with clinically relevant bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: Number of patients with a composite major adverse cardiovascular or cerebrovascular events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Histological rejection in skin flap
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Histological rejection in transplanted solid organ
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: percentage of time in the target sedation range
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of individuals who experienced adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Face Name Associative Memory Task effects
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Electroencephalography (EEG) effects
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: rate of microbiological eradication
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: rate of clinical cure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Remission at 52 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of postoperative delirium
Endpoint domain: Adverse events/effects
Primary endpoint: Average percent time in glucose range
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Biochemically verified 7-day point-prevalence abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in knee integral vBMC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: proportion of patients with eTICI 2b-3 at the end of the treatment procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: proportion of patients with mRS 0-2 at 90 (± 20) days after procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Triglyceride/HDL-cholesterol ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Concentration of Viral RNA in Adipose Tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Rate of Inflammatory Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Rate of Inflammatory Gene Expression in Adipose Tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Plasma levels of ficolin-2 at day 5 in ng/ml
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: [18F]DPA-714 PET/MRI metabolic data
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Patient smoking abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline pain during palpation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Distance from skin to Hyoid bone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tongue Thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Distance from Jaw to Hyoid bone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Independent Living Skills
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Change in haematocrite levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in the number of blood transfusions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Incidence of Treatment-Emergent Adverse Events in healthy volunteers
Endpoint domain: Adverse events/effects
Primary endpoint: Difference in tolerance scores in healthy volunteers
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Incidence of Treatment-Emergent Adverse Events in cancer patients
Endpoint domain: Adverse events/effects
Primary endpoint: Difference in tolerance scores in cancer patients
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Postoperative liver failure prediction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Severe aGVHD during 100 days after transplantation
Endpoint domain: Adverse events/effects
Primary endpoint: Sensitivity of urinalysis by PROUD analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of urinalysis by PROUD analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain Catastrophising Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Strengths and Difficulties Questionnaire (SDQ) score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Positive prick-test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Freedom from AF/AFL/AT >30 seconds through 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of defined Major Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: change in ventilation pattern complexity and variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: change in elbow pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnosis of late gestational diabetes mellitus (GDM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Postoperative Bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: Outcome of fireworks eye injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in sizes of pancreatic fluid collections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Prostate health as assessed by the International Prostate Symptom Score (IPSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Extracellular Vesicles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Prevalence of cardiovascular complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cardiac rehabilitation attendance
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Compliance of a smartphone application
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Satisfaction of a smartphone application
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Fraction of [¹⁴C] radioactivity excreted into urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Fraction of [¹⁴C] radioactivity excreted into feces
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Absolute bioavailability of BI 685509
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from the baseline in ADAS-Cog
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change from baseline intrahepatic lipid percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from baseline hepatic steatosis percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change of liver function parameters level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of lipid panel
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: White Matter Hyperintensity burden
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Kidney biopsy features
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Kidney biopsy transcriptomic signature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Kidney cell type composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes of Short Physical Performance Battery (SPPB)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Detection capability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Accuracy of DCNN tract classification for detection of ESM-defined eloquent white matter pathways
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Accuracy of DCNN tract classification for prediction of eloquent white matter pathways providing no postoperative deficits
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Strength of association between local efficiency of preoperative network and functional measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in time spent in moderate to vigorous physical activity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in School absence data
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Success of local anesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants presenting with a full stomach
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Reduction in CH attack frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of treatment-emerged adverse events in TENS treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of treatment-emerged adverse events in ONS treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Immunogenicity of wild type neutralizing antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: The incidence of adverse reactions (AR)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Cure of the patient
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of oxidative low-density lipoprotein (ox-LDL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Postoperative Quality of Recovery
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Parent-reported individual gastrointestinal (GI) symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Parent-reported individual GI- and feeding-related behaviors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of infants with specific GI characteristics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change From Baseline in the Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Parts I, II and III
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change From Baseline in the EuroQol 5 Dimension 5 Level (EQ-5D-5L) Index
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Maternal pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maternal sedation level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients with palliative care consults placed within 48 hours after enrollment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Hospital-free days by day 90
Endpoint domain: Mortality/survival
Primary endpoint: Outcome Quality Indicators
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Cardiac Rehab Sessions Attended
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: relative bioavailability of TAF and TFV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: relative bioavailability of FTC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: relative bioavailability of DTG
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: relative bioavailability of potential interaction and pharmacokinetics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of PEEK implants
Endpoint domain: Adverse events/effects
Primary endpoint: major amputation for vascular reasons
Endpoint domain: Mortality/survival
Primary endpoint: dual-task costs while walking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: dual-task costs while standing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: dual-task costs while execution of isometric task
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BBS scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: MFIS scale
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Controlled attenuation parameter (CAP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Prevalence of cirrhosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change from Baseline Balance Ability at 12 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urine Cotinine Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in oxygenation of feet and lower legs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Circulatory outcomes
Primary endpoint: complete pathologic response (pCR) rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with serious or non-serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Area Under the Concentration-time Curve of BI 474121 in Plasma (AUC0-∞)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with adverse events as assessed by CTCAE v5.0
Endpoint domain: Adverse events/effects
Primary endpoint: Immunogenicity of anti SARS-CoV-2 neutralizing antibody
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Positive prediction rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Negative prediction rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: False discovery rate of the anatomical object labeling function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: False discovery rate of the anatomical view identification function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of serious and non-serious device- and/or procedure-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Mean change in Maximum Active Mouth Opening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pulmonary Index of Microcirculatory Resistance (PIMR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Right Ventricle Index of Microcirculatory Resistance (RV-IMR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: OCT-derived pulmonary artery wall thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Knowledge about Opioid Use Disorders and Treatment
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Hemodynamic
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Partial pressure of carbon dioxide in arterial blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: early active range of motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change From Baseline in CLASI-A Sub-Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: K-WOMAC Pain Subscale
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Change in Suit Usability
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Suit Safety measured by patient-reported pain
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Functional Suit effect measured by peak deadlift pull force
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in caregiver-rated Hyperphagia Questionnaire for Clinical Trials (HQ-CT) score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing